US 12,480,162 B2
Detection of metastatic disease and related methods
Lonnie D. Shea, Ann Arbor, MI (US); Robert S. Oakes, College Park, MD (US); Grace Bushnell, Ann Arbor, MI (US); and Jacqueline S. Jeruss, Ann Arbor, MI (US)
Assigned to THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
Appl. No. 16/754,042
Filed by THE REGENTS OF THE UNIVERSITY OF MICHIGAN, Ann Arbor, MI (US)
PCT Filed Oct. 8, 2018, PCT No. PCT/US2018/054859
§ 371(c)(1), (2) Date Apr. 6, 2020,
PCT Pub. No. WO2019/071257, PCT Pub. Date Apr. 11, 2019.
Claims priority of provisional application 62/571,702, filed on Oct. 12, 2017.
Claims priority of provisional application 62/569,460, filed on Oct. 6, 2017.
Prior Publication US 2020/0323893 A1, Oct. 15, 2020
Int. Cl. C12Q 1/6886 (2018.01)
CPC C12Q 1/6886 (2013.01) 22 Claims
OG exemplary drawing
 
1. A method comprising:
a) measuring a level of expression of a panel of genes, RNAs, or proteins, in a test sample obtained from a synthetically-engineered pre-metastatic niche (pMN) implanted in a subject having or suspected of having cancer, wherein the test sample comprises immune cells and stromal cells and wherein less than 10% of the cells in the test sample are tumor cells;
b) determining that the subject has an increased metastatic potential based upon the level of expression of the panel of genes, RNAs, or proteins in the test sample relative to a control level or a level of expression at an earlier time point; and
c) administering an anti-metastatic disease treatment to the subject determined in b) to have an increased metastatic potential, to thereby treat the subject for metastasis,
wherein the subject is a mammal, and
wherein the panel of genes, RNAs, or proteins comprises two or more of the following: S100 Calcium Binding Protein A8 (S100a8), S100 Calcium Binding Protein A9 (S100a9), Peptidoglycan Recognition Protein 1 (Pglyrpl), Lactotransferrin (Ltf), Cathelicidin Antimicrobial Peptide (Camp), Elastase 2 (Ela2), Chitinase (Chi313), Bone Morphogenetic Protein 15 (Bmp15), C-C Motif Chemokine Ligand 22 (Cc122), C-C Motif Chemokine Receptor 7 (Ccr7), granulocyte colony stimulating factor (G-CSF), interleukin 1-alpha (IL-1a), interleukin-12p70 (IL-12p70), interleukin-6 (IL-6), C-X-C motif chemokine 5 (Cxc15), interleukin-15 (IL-15), C-X-C motif chemokine 10 (Cxcl10), C-C motif chemokine ligand 2 (Cc12), C-X-C motif chemokine 9 (Cxc19), and C-C motif chemokine ligand 5 (Cc15).